The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...
A ketamine-based nasal spray is officially the first and only standalone therapy available for treatment-resistant depression in the US.
The US FDA has approved the first of its kind ketamine-based nasal spray which is supposed to act as a standalone therapy for ...
People using weed for medical purposes are as likely -- or more -- to become addicted to cannabis as recreational tokers, a ...
On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
As more cases of bird flu emerge across the country, public health leaders in New York City are watching warily -- and making ...
Here are the top health headlines for the week of Jan. 19, 2025. A nasal spray derived from ketamine gets federal clearance ...